Neuralink
Neuralink's N1 implant and R1 surgical robot are in the PRIME and GB-PRIME early-feasibility trials, with public trackers reporting 21 enrolled participants across five therapeutic programs in four countries and zero serious adverse device events;…
- Country
- United States
- Ticker
- private
Brain–computer interface
FDA IDE trial
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biomedical engineering & implants | regenerative-personalized | Medium | → |
| Neurointerfaces & brain–computer interfaces | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.